喬治Arida

George是BlueWillow Biologics領導團隊的一員，BlueWillow Biologics是一家臨床階段公司，開發並實現新一代新穎的鼻內疫苗，以引發粘膜和體液免疫，以保護全球人群免受呼吸道感染、性傳播疾病和食物過敏的影響。喬治還是30Ventures的創始人兼董事總經理，30Ventures是一家總部位於麥迪遜的早期風險投資公司，專注於醫療保健機會。George繼續擔任投資組合公司AIQ Solutions和POPS Diabetes Care的董事會成員。George此前曾擔任Zystor Therapeutics(被BioMarin Pharmaceutical Inc. - NASDAQ: BMRN收購)、Nerites Corporation(被Kensey Nash收購，現為DSM - Euronext: DSM)、Celleration, Inc.(被Alliqua BioMedical, Inc. - NASDAQ: ALQA收購)和Chromatin, Inc.(被S&W Seeds - NASDAQ: SANW收購)的董事會主席。George是中美洲醫療保健投資者網絡的創始董事，該網絡由40多家活躍於早期醫療保健投資的區域風險投資公司組成，並擔任各種孵化器、加速器、風險會議和芝加哥聯邦儲備銀行的顧問。喬治還為哈林頓發現研究所和BioMotiv提供建議。他在芝加哥大學格雷厄姆商學院任教，並在布斯商學院和威斯康辛大學商學院客座講授創業和風險投資的主題。George此前曾擔任Capital Resource Advisors(一家位於芝加哥的金融服務公司，被Rogers-Casey收購)的首席財務官，在此之前，他在U.S. Filter、Betz Laboratories和Alar Engineering的工業水和特種化學品行業工作了12年。George擁有伊利諾伊大學化學工程學士學位和芝加哥大學布斯商學院工商管理碩士學位。

Celleration

凱文Etzkorn

Etzkorn先生為基金帶來了超過8年的風險投資經驗和超過10年的業務和技術管理經驗。加入Heron之前，他是CID Capital(生命科學和技術風險基金)的負責人。在CID任職期間，他的投資組合職責包括:Axiomed Spine Corporation, Bridge Semiconductor Corporation, EKOS Corporation, HyperNex, Inc.(被Nova measurement Instruments收購)和Renal Solutions, Inc.(被Fresenius Medical Care收購)。Prior to joining CID Capital in 2001, Mr. Etzkorn spent thirteen years in the U.S. Navy in a variety of technical and supervisory roles, most recently as a Nuclear Engineer and Communications Officer aboard the Fleet Ballistic Missile Submarine USS ALASKA, where he was responsible for the establishment and management of its Information Technology Department. He also served as an Assistant Professor in the Department of Naval Science at the University of Illinois. Mr.Etzkorn has served as an advisor to the National Science Foundation for the Small Business Innovation Research (SBIR)Program and as an advisory board member for the Telemark Group, a New York based investment fund. He received his M.B.A. from the University of Illinois and a bachelor's degree in Electrical and Computer Engineering from the University of Wisconsin.Currently, Mr. Etzkorn serves as a Director on the Board of AirXpanders and Celleration and is a board observer for BioSET, Inc. He also led the firm's investment in Atlantis Components, Inc. which was sold to Astra Tech AB, a subsidiary of AstraZeneca, in 2007.

Celleration

Somu蘇

Subramaniam先生是New Science Ventures的聯合創始人和管理合夥人，任職於Achronix Semiconductor Corporation、Alexar Therapeutics、Ario Pharmaceuticals、Cambridge Epigenetix、Dali Wireless、Dezima Pharma、塔斯Therapeutics、Oxyrane、Resolve Therapeutics、TigerText、Vaultive和iCAD的董事會。他還擔任Ception(被Cephalon收購)、BioVex(被Amgen收購)、Lightwire(被Cisco收購)和K2M(被Welsh Carson收購)的董事會成員。在成立NSV之前，Subramaniam先生是McKinsey & Company的董事，在那裏他為製藥、醫療設備、生物技術、光子學、軟件和半導體行業的領先跨國公司提供谘詢。在麥肯錫，他是戰略實踐、技術實踐、生物技術集團和醫療實踐的領導者。他還在公司的投資委員會任職，並領導其股權投資組合委員會。Subramaniam先生持有the Indian Institute of Technology的學士學位和Harvard Business School的工商管理碩士學位。

Celleration